Catabasis Pharmaceuticals Inc.

2.24-0.1300-5.49%Vol 771.66K1Y Perf -57.15%
Apr 16th, 2021 16:00 DELAYED
BID2.20 ASK2.28
Open2.35 Previous Close2.37
Pre-Market- After-Market2.24
 - -  - -%
Target Price
5.00 
Analyst Rating
Strong Buy 1.00
Potential %
123.21 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap52.45M 
Earnings Rating
Neutral
Price Range Ratio 52W %
13.49 
Earnings Date
11th May 2021

Today's Price Range

2.152.35

52W Range

1.258.59

5 Year PE Ratio Range

-0.6000-0.9000

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-17.34%
1 Month
-37.43%
3 Months
-14.18%
6 Months
-64.22%
1 Year
-57.15%
3 Years
-87.42%
5 Years
-95.73%
10 Years
-

TickerPriceChg.Chg.%
CATB2.24-0.1300-5.49
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.34-0.45-32.35
Q03 2020-0.51-0.56-9.80
Q02 2020-0.46-0.53-15.22
Q01 2020-0.41-0.50-21.95
Q04 2019-0.62-0.5511.29
Q03 2019-0.63-0.5611.11
Q02 2019-0.56-0.62-10.71
Q01 2019-0.60-0.62-3.33
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.1874.29Positive
6/2021 QR-0.17-108.95Negative
12/2021 FY-0.67--
12/2022 FY-0.64--
Next Report Date11th May 2021
Estimated EPS Next Report-0.18
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume771.66K
Shares Outstanding23.42M
Trades Count3.67K
Dollar Volume2.81M
Avg. Volume5.30M
Avg. Weekly Volume491.92K
Avg. Monthly Volume443.14K
Avg. Quarterly Volume6.00M

Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) stock closed at 2.24 per share at the end of the most recent trading day (a -5.49% change compared to the prior day closing price) with a volume of 771.71K shares and market capitalization of 52.45M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 27 people. Catabasis Pharmaceuticals Inc. CEO is Jill C. Milne.

The one-year performance of Catabasis Pharmaceuticals Inc. stock is -57.15%, while year-to-date (YTD) performance is 4.67%. CATB stock has a five-year performance of -95.73%. Its 52-week range is between 1.25 and 8.59, which gives CATB stock a 52-week price range ratio of 13.49%

Catabasis Pharmaceuticals Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 1.60, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -80.26%, a ROC of -78.23% and a ROE of -93.77%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Catabasis Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.18 for the next earnings report. Catabasis Pharmaceuticals Inc.’s next earnings report date is 11th May 2021.

The consensus rating of Wall Street analysts for Catabasis Pharmaceuticals Inc. is Strong Buy (1), with a target price of $5, which is +123.21% compared to the current price. The earnings rating for Catabasis Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Catabasis Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Catabasis Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 35.19, ATR14 : 0.30, CCI20 : -169.99, Chaikin Money Flow : -0.24, MACD : -0.17, Money Flow Index : 27.62, ROC : -16.10, RSI : 37.30, STOCH (14,3) : 11.11, STOCH RSI : 0.00, UO : 37.50, Williams %R : -88.89), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Catabasis Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Catabasis Pharmaceuticals Inc.

Catabasis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted, a linker-drug discovery platform. The company's primary focus is on treatments for rare diseases. Its product pipeline includes CAT-1004, an oral small molecule for the treatment of Duchenne muscular dystrophy, CAT-2054 for the treatment of hypercholesterolemia and CAT-4001 which is used for the treatment of rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

CEO: Jill C. Milne

Telephone: +1 617 349-1971

Address: 100 High Street, Boston 02110, MA, US

Number of employees: 27

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

63%37%

Bearish Bullish

52%48%

News

Stocktwits